Sarcotein has developed advanced technology to improve the diagnosis and management of patients with failing hearts.

The technology behind CS started with a major discovery in cell biology at the University of California, San Francisco. This finding was translated into a clinical test by Sarcotein Diagnostics and successfully tested at Cedars-Sinai Medical Center, which has the world’s most prolific heart transplant program. CS is now available as an ELISA test kit for commercial and research use.

Our History


Dr. TingTing Hong and Dr. Robin Shaw discovered that the scaffolding protein, cBIN1, organizes microdomains responsible for calcium release and excitation-contraction (EC) coupling and is decreased in failing human hearts.


Sarcotein Diagnostics was founded using a technology discovered at the University of California, San Francisco (UCSF) (Plos Biology 2010, Nature Medicine 2014).


Sarcotein collaborated with UCSF to further develop and standardize the cBIN1 assay.


The CS assay was successfully tested on a cohort of heart failure patients from Cedars-Sinai Medical Center (JAMA Cardiology 2018).


The assay was standardized for commercial and research use. Sarcotein partnered with Avioq, Inc. provided pre-plated ELISA kits and standards for onsite use or to run the assay at Avioq with plasma provided.


The CS assay was finalized and became ready to purchase for commercial and research use.